Qingdao Baheal Medical Future Growth
Future criteria checks 5/6
Qingdao Baheal Medical is forecast to grow earnings and revenue by 22.6% and 14.7% per annum respectively. EPS is expected to grow by 22.5% per annum. Return on equity is forecast to be 24.5% in 3 years.
Key information
22.6%
Earnings growth rate
22.5%
EPS growth rate
Healthcare earnings growth | 21.8% |
Revenue growth rate | 14.7% |
Future return on equity | 24.5% |
Analyst coverage | Low |
Last updated | 13 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 11,775 | 1,316 | N/A | 970 | 3 |
12/31/2025 | 9,972 | 1,079 | N/A | 685 | 3 |
12/31/2024 | 8,643 | 855 | N/A | 689 | 3 |
12/31/2023 | 7,564 | 656 | 480 | 610 | N/A |
9/30/2023 | 7,486 | 651 | 283 | 392 | N/A |
6/30/2023 | 7,414 | 588 | 377 | 492 | N/A |
3/31/2023 | 7,336 | 537 | 470 | 589 | N/A |
12/31/2022 | 7,510 | 502 | 200 | 306 | N/A |
9/30/2022 | 7,336 | 458 | 327 | 411 | N/A |
6/30/2022 | 7,436 | 451 | 264 | 314 | N/A |
3/31/2022 | 7,286 | 423 | 136 | 170 | N/A |
1/1/2022 | 7,052 | 422 | 154 | 181 | N/A |
9/30/2021 | 7,038 | 421 | 524 | 543 | N/A |
6/30/2021 | 6,797 | 349 | 210 | 228 | N/A |
3/31/2021 | 6,291 | 303 | -66 | -51 | N/A |
12/31/2020 | 5,879 | 273 | -133 | -117 | N/A |
12/31/2019 | 4,849 | 210 | 40 | 43 | N/A |
12/31/2018 | 3,652 | 258 | 37 | 53 | N/A |
12/31/2017 | 3,096 | 222 | 149 | 160 | N/A |
12/31/2016 | 3,034 | 184 | N/A | 88 | N/A |
12/31/2015 | 2,392 | 73 | N/A | 82 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301015's forecast earnings growth (22.6% per year) is above the savings rate (2.9%).
Earnings vs Market: 301015's earnings (22.6% per year) are forecast to grow faster than the CN market (22.3% per year).
High Growth Earnings: 301015's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301015's revenue (14.7% per year) is forecast to grow faster than the CN market (13.7% per year).
High Growth Revenue: 301015's revenue (14.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301015's Return on Equity is forecast to be high in 3 years time (24.5%)